While Celldex Therapeutics Inc has underperformed by -0.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLDX fell by -51.46%, with highs and lows ranging from $47.00 to $18.61, whereas the simple moving average fell by -34.29% in the last 200 days.
On March 20, 2025, Morgan Stanley started tracking Celldex Therapeutics Inc (NASDAQ: CLDX) recommending Overweight. A report published by UBS on February 13, 2025, Initiated its previous ‘Buy’ rating for CLDX. Citigroup also rated CLDX shares as ‘Buy’, setting a target price of $70 on the company’s shares in an initiating report dated October 07, 2024. Goldman Initiated an Neutral rating on September 30, 2024, and assigned a price target of $45. Wolfe Research September 27, 2024d its ‘Outperform’ rating to ‘Peer Perform’ for CLDX, as published in its report on September 27, 2024. Stifel’s report from June 18, 2024 suggests a price prediction of $58 for CLDX shares, giving the stock a ‘Buy’ rating. Wolfe Research also rated the stock as ‘Outperform’.
Analysis of Celldex Therapeutics Inc (CLDX)
Further, the quarter-over-quarter decrease in sales is -71.56%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Celldex Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -26.84% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 18.91, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and CLDX is recording an average volume of 877.29K. On a monthly basis, the volatility of the stock is set at 6.03%, whereas on a weekly basis, it is put at 4.42%, with a loss of -1.29% over the past seven days. Furthermore, long-term investors anticipate a median target price of $62.08, showing growth from the present price of $19.88, which can serve as yet another indication of whether CLDX is worth investing in or should be passed over.
How Do You Analyze Celldex Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.54%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 109.76% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CLDX shares are owned by institutional investors to the tune of 109.76% at present.
